News Hub | News Direct

All Industries


Article thumbnail News Release

Sierra Metals looking to build on success in 2023 for a very productive 2024

Sierra Metals Inc

Sierra Metals CEO Ernesto Balarezo joined Steve Darling from Proactive to discuss the company’s financial performance for the three months and full year ending December 31, 2023. Sierra Metals reported robust results, with revenue reaching $60.6 million for the fourth quarter, marking a notable increase of 58% compared to Q4 2022. Additionally, the company achieved an Adjusted EBITDA of $12.2 million and produced 21.1 million pounds of Copper equivalent, representing a substantial 78% increase from Q4 2022. Balarezo highlighted to Proactive that Sierra Metals aims to capitalize on its strong performance in 2023 by leveraging strategic initiatives and operational enhancements. With the Level 1120 permit now secured at Yauricocha, the company anticipates ramping up production to full capacity later in 2024. Additionally, in Bolivar, Sierra Metals is focused on constructing a new tailings facility, which is expected to increase production capacity by 50% to 7,500 tonnes per day over the next two to three years. In terms of exploration, Sierra Metals is actively seeking partnerships to develop its assets and maximize their potential. The company remains committed to advancing its projects and is poised to publish new NI 43-101 mineral reserve and resource reports in the near future. Overall, Sierra Metals' strong financial performance and strategic initiatives position the company for continued growth and success in the mining sector. With a focus on operational excellence, expansion projects, and exploration partnerships, Sierra Metals is well-positioned to create long-term value for its shareholders and stakeholders alike. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

March 28, 2024 08:28 AM Eastern Daylight Time

Video
Article thumbnail News Release

Montage Gold Aims to Establish a Leading Gold Mining Company in Africa

Montage Gold Corp

Montage Gold Inc CEO Martino De Ciccio joined Steve Darling from Proactive to share exciting developments as the company strives to establish a multi-asset gold mining enterprise focused on Africa. Drawing on his nine-year tenure at Endeavor, De Ciccio's transition to Montage Gold reflects a strategic move to capitalize on the burgeoning opportunities within the gold mining sector, backed by support from London investors. Central to Montage Gold's strategy is its flagship project, the Kone project located in Cote d'Ivoire, which is currently at the DFS (Definitive Feasibility Study) stage. The project holds immense promise, with projections indicating annual production of over 300,000 ounces for the first eight years, at an industry-leading cost of $1,000 per ounce, and a robust 16-year mine life. These impressive metrics firmly position the Kone project as a standout venture in Africa, distinguished by its scale, quality, and the favorable operational environment in Cote d'Ivoire. Over the past year, Montage Gold has made significant strides under new London backing, focusing on updating the feasibility study to reflect a higher-grade deposit. The company successfully completed a financing round, surpassing its initial target by raising $35 million. This funding infusion will propel Montage Gold through to the construction phase, facilitating additional drilling to enhance the mine plan, initiating digital engineering and land compensation efforts, and streamlining financing and permitting processes. Montage Gold's extensive land package offers substantial exploration potential beyond the Kone deposit, which already hosts an impressive 4 million ounces of gold. The presence of multiple mineralized trends and identified targets near the Kone deposit augurs well for the discovery of additional smaller deposits, further bolstering the project's economic viability. Operating in Cote d'Ivoire provides Montage Gold with distinct advantages, including established mining infrastructure, easy site access, and a favorable regulatory environment. These factors contribute to the company's confidence in its ability to execute its ambitious plans and establish a significant gold mining presence in Africa. As Montage Gold progresses through 2024 under De Ciccio's leadership, the company is poised to realize its vision of becoming a leading player in the African gold mining landscape, with the Kone project serving as a cornerstone of its success. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

March 28, 2024 08:25 AM Eastern Daylight Time

Video
Article thumbnail News Release

MTB Metals Advances Porphyry Copper-Gold Exploration in BC's Golden Triangle

MTB Metals

MTB Metals CEO Lawrence Roulston joined Steve Darling from Proactive to share news about the company advances its exploration projects in the Golden Triangle of British Columbia, covering nearly 600 square kilometres across six distinct projects. The company's primary focus is on the Telegraph project, a porphyry copper-gold prospect located near four other world-class porphyries with identical geology. Roulston told Proactive that during recent discussions at the PDAC conference and subsequent meetings, MTB Metals has attracted considerable interest from major mining companies for potential joint ventures or strategic investments, particularly in the Telegraph project. This interest stems from the project's promising location and the substantial exploration potential it holds. In 2021, MTB Metals consolidated a large property area and has conducted three field seasons of exploration. Towards the end of the last season, four drill holes were completed across a 3.3-kilometre trend within the Telegraph project, indicating a large-scale porphyry system. While retail investors showed limited enthusiasm for the initial drilling results, major mining companies recognized the broader potential of the system, understanding that these initial holes only begin to reveal the project's capacity. Ralston plans to further explore the already drilled area and other porphyry centers within the 350-square-kilometre property, emphasizing the project's significant exploration and development potential. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

March 28, 2024 08:23 AM Eastern Daylight Time

Video
Article thumbnail News Release

Medicus Pharma says U.S. FDA has provided comments on Phase 2 Clinical Protocol of SKNJCT-003

Medicus Pharma

Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma joined Steve Darling from Proactive to share significant updates regarding the company's interaction with the U.S Food and Drug Administration (FDA). Medicus Pharma has received comments from the FDA, pertaining to its recent study findings and regulatory submissions. The FDA's feedback regarding the study results is considered exploratory, with specific requests directed towards providing additional data from clinical studies to support the doses of 100μg and 200μg of micro-array needles containing doxorubicin. Additionally, the FDA has requested an updated investigator brochure, incorporating insights from the clinical studies SKNJCT-001 and SKNJCT-002, focusing particularly on adverse events and dose-limiting toxicities at each dose level. Dr. Bokhari conveyed to Proactive that the SKNJCT-001 study successfully met its primary objective of assessing safety and tolerability. The investigational product, D-MNA, demonstrated favorable safety profiles across all dose levels among the thirteen participants enrolled in the study. This encouraging outcome underscores the potential of D-MNA as a safe and well-tolerated therapeutic option. In response to the FDA's requests, Medicus Pharma is committed to making a comprehensive submission in the second quarter of 2024. This submission will include the requested data and an updated investigator brochure, meticulously incorporating insights from the SKNJCT-001 and SKNJCT-002 studies. Furthermore, the submission will encompass Chemistry, Manufacturing, and Controls (CMC) stability data, ensuring a comprehensive and robust dossier. Dr. Bokhari reiterated Medicus Pharma's dedication to adhering to regulatory guidelines and fostering transparent communication with regulatory authorities. By addressing the FDA's queries and providing comprehensive data, the company aims to facilitate the regulatory review process and advance the development of D-MNA towards potential regulatory approval. In summary, Medicus Pharma remains steadfast in its commitment to advancing innovative therapies while upholding the highest standards of safety and efficacy. The company's proactive engagement with regulatory agencies reflects its dedication to bringing impactful treatments to patients in need. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

March 28, 2024 08:21 AM Eastern Daylight Time

Video
Article thumbnail News Release

Pantheon Resources Eyes Resource Upgrade and Financing Developments

Pantheon Resources PLC

Pantheon Resource CEO Jay Cheatham and Justin Hondris, Head of Finance and Corporate Development joined Steve Darling from Proactive to detail their financial and operational status, along with upcoming projects and collaborations. The company's General and Administrative expenses rose slightly to $4 million, reflecting its growth trajectory, and reported a loss of $5.7 million. However, they have a robust cash balance of $8.7 million. An anticipated update from an independent expert report by Netherland, Sewell and Associates is expected to significantly upgrade the resource estimates for the Kodiak project, particularly noting improved reservoir properties due to its shallower depth. This enhancement stems from recent acquisitions in a lease sale, promising better porosity and permeability characteristics. CEO Jay Cheatham also commented on the neighbouring activity by 88 Energy, noting close proximity and collaboration between the two companies' operations teams, especially regarding the Hickory 1 well. Pantheon is optimistic that positive outcomes from 88 Energy's projects could have favourable implications for their operations. Furthermore, Justin Hondris, involved in finance and corporate development, highlighted ongoing discussions regarding vendor offtake financing, with an update planned for the end of the quarter. This financing is crucial for advancing Pantheon's significant assets and ambitions, although immediate cash influx from this arrangement should not be anticipated by investors at this stage. Overall, Pantheon Resources is positioned for a busy period ahead, with significant updates on financing and project evaluations forthcoming. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

March 28, 2024 08:18 AM Eastern Daylight Time

Video
Article thumbnail News Release

Ventripoint Diagnostics Provides Corporate Update and Announces Conference Call

Ventripoint Diagnostics Ltd.

Toronto, Ontario – TheNewswire – March 28, 2024 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ); ( OTC:VPTDF) is pleased to provide a corporate update on the Company’s current status and the outlook for 2024. The Company entered 2024 continuing the refinement of its foundational technology and is currently strengthening its operations to enable more effective marketing, sales and customer support.  Hugh MacNaught assumed the role of Interim President and CEO in early February. “ During the past six weeks I have had the opportunity to more fully assess the technology, team and market opportunity and have identified key areas of focus for the company as it progresses towards the growth phase of its development,” commented Mr. MacNaught. “The enhancements to echocardiography enabled by VMS+ provide greater efficiency and reduced cost to healthcare providers while improving accessibility and comfort to patients.  The Company has no debt, a dedicated and motivated team, and a well-differentiated product. Our highest priority is to drive clinical awareness and adoption of our AI technology by healthcare providers in 2024”. Sales, Marketing, and Distribution Ventripoint’s highest priority for 2024 is to demonstrate its ability to establish commercial traction with product that has obtained regulatory clearance in key markets such as the U.S., E.U., U.K., and Canada.     During the current quarter key activities include: 1.   Recruitment and on-boarding of a Strategic Partnerships Executive, Bart Hendriks, whose principal focus is on the E.U and U.K markets; 2.   Communicating with the existing customer base to assess the use of VMS+ in real life clinical settings and develop deeper insights into clinical indications and procedure volumes; 3.   Meeting with E.U. and U.K. distributors to review 2023 performance and 2024 objectives. We are working to improve the efficiency of installation, training and acceptance at customer sites to enable faster implementation of VMS+ products; 4.   Releasing VMS+3.2 with enhanced ease of use and 3D visualization features, for sale; 5.   Conducted an advanced training workshop in Germany led by Dr. med. Kai Thorsten Laser, Deputy Director and Senior Physician of the Clinic for Paediatric Cardiology and Congenital Heart Defects at the Heart and Diabetes Center North Rhine-Westphalia, Germany. 6.   Identifying the conferences in 2024 that align most closely with Ventripoint’s commercial objectives.  Ventripoint is a Silver Sponsor for the 2024 AEPC meeting in May, where Ventripoint is a Silver Sponsor and will be providing demonstrations and a product workshop at the conference; 7.   Engaging the Visual Friday agency to perform a refresh of the Ventripoint brand. Style elements will be introduced in the next quarter; 8.   Initiating an update to the corporate website. This includes moving the site to a more flexible and robust platform and will include incorporation of style elements generated by the brand refresh; 9.   Initiating adoption of a CRM. This will integrate input from distributors, facilitate effective forecasting, and enable efficient manufacturing and supply chain management; 10.   Initiate recruitment of an MBA intern to develop market insights and intelligence. This is an important first step in evolving the corporate culture to addressing unmet clinical needs and ensuring optimal product/market fit. 11.   Closing the sale of a VMS+3.2 system to a top 10 U.S. cardiology centre; 12.   Engaging in ongoing discussions with partner Ascend regarding marketing, sales and development opportunities; 13.   Continuing to work with the Ollie Hinkle Heart Foundation to introduce VMS+ to paediatric cardiology centres. Product Development and Manufacturing During the current quarter key activities include: 1.   Release of VMS+3.2 for sale.  The key benefits to this update are related to the removal of magnets from the sensors, eliminating a calibration step and simplifying clinical workflow; 2,   Moving towards completion of validation and verification testing for VMS+4.0; 3.   Engaging service provider to perform Medical EMC Testing for Professional Healthcare Environment to comply with updated IEC 60601 standard; 4.   Preparation for submission of VMS+4.0 to FDA for 510(k) clearance; 5.   Passing the semi-annual factory inspection for NRTL certification; 6.   Initiating creation of a technology roadmap; 7.   Review of project management process and procedures; 8.   Review of supply chain, inventory and manufacturing. Finance During the current quarter key activities include: 1.   Working with auditors to complete the annual audit; 2.   Reviewing capital requirements for the current year. After review and discussion, the Board of Directors has identified the need to secure off-the-market financing to support the company’s operations in 2024. An announcement will be made shortly concerning this matter. Added Mr. MacNaught “Over the next month we will continue to focus on closing sales for VMS+3.2, preparing for the AEPC conference in May, submitting VMS+4.0 to FDA for 510(k) clearance and optimizing our internal processes to support growth.  During this time, I will be devoting more time and attention to the U.S. market to ensure that Ventripoint achieves a high rate of success.” Conference Call The Company will hold a conference call to discuss this update. Wednesday April 3 rd, 2024 11.00 am Eastern Time Participants can access the call by dialing 1-844-763-8274 or +1-647-484-8814. It is recommended that you call 10 minutes before the scheduled start time to avoid the queue.   After the call, an audio recording will be made available via telephone for one month, until end of day May 3rd. The recording can be accessed by dialing 1-855-669-9658 or +1-604-674-8052 and using the access code 5078#.   A written transcript of the call will be available on Ventripoint’s website shortly after its conclusion.   About Ventripoint Diagnostics Ltd. Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada. For further information, please contact: Jonathan Robinson JRobinson@oakhillfinancial.ca 416-669-1001 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. Forward Looking Statements This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends'' and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

March 28, 2024 08:16 AM Eastern Daylight Time

Article thumbnail News Release

Xalles Holdings: nurturing tech startups towards lucrative exits

Xalles Holdings

Xalles Holdings (OTC:XALL) chairman Thomas Nash takes Proactive's Stephen Gunnion through the company's strategy of acquiring technology companies with strong assets and management teams, as well as the potential for significant growth. Nash explained that Xalles targets early-stage companies, guiding them through a business lifecycle that spans from incubation to acceleration and growth, with the ultimate aim of achieving a profitable exit. Nash emphasized the importance of the management team and key personnel in these acquisitions, stating that companies remain wholly owned subsidiaries, retaining their original management to ensure motivation and alignment with Xalles Holdings’ goals. Xalles Holdings does not adopt a hands-on approach in the daily operations of its acquisitions but provides support in areas like financial backing, marketing, PR, and leveraging business development networks, Nash said. This support is aimed at helping subsidiaries refine their business plans and navigate towards financial milestones effectively. The company's acquisition strategy does not have a fixed timeframe, offering flexibility to adapt to each company's unique needs and market conditions. This strategy includes various phases, from early-stage incubation with Exotic Studio to acceleration with Exogamous Advisors and eventually to a formal acquisition under the RISE model, which stands for Roll In Selected Exit. Pending acquisitions include 100% of Fluid Tech and a stake in WooSender, demonstrating Xalles Holdings’ diverse portfolio. The company also reported a 234% growth in revenue year-over-year for the third quarter of 2023, marking its ninth consecutive quarter of revenue growth, attributed to strategic acquisitions and effective support for these companies. Contact Details Proactive North America Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

March 28, 2024 08:15 AM Eastern Daylight Time

Video
Article thumbnail News Release

NeuroOnes’s Innovative Electrode Brain Monitoring Seeks To Provide Insights Into Neurological Disorders

Benzinga

by Meg Flippin, Benzinga When it comes to diseases of the brain, epilepsy is among the more common ones, affecting roughly 50 million people globally. This condition arises from various factors that disrupt normal brain activity, such as strokes, brain tumors, traumatic brain injuries, and infections of the central nervous system, with the annual cost of managing epilepsy approximately $28 billion. Current treatments, despite the availability of over 20 antiepileptic drugs (AEDs), fall short of effectively managing the condition for all patients. Approximately 36% of individuals with epilepsy experience uncontrolled seizures, which could have a significant impact on their quality of life and mortality. For many, the only solution is surgery. Better Outcomes With Electrodes NeuroOne Medical Technologies Corp. (NASDAQ: NMTC) is hoping to achieve better outcomes for patients suffering from neurological disorders with its high-definition, minimally invasive thin film electrodes used for intracranial monitoring. The electrodes are implanted inside the skull to record brain activity and the company says they may someday be able to treat diseases like epilepsy. NeuroOne’s Evo® Cortical Electrode portfolio consists of various configurations of strips and grid electrodes made with polyimide thin film, which reduce trauma to the brain. They are a less invasive implant because the material is flexible, thin and light. They can monitor brain activity for less than 30 days. NeuroOne’s Evo® sEEG Electrode technology enables the recording and monitoring of brain activity for less than 30 days. With the technology, the company says doctors can identify the right foci zones to determine the best treatment for patients. The company has said its technology provides new options for surgical placement and potentially smaller incisions, as well as for lower inflammation compared to the bulky electrodes currently on the market, while also enabling the pairing of diagnostic and therapeutics in one offering. With proven placement accuracy and enhanced signal quality, physicians can capture the vital data they need to support more confident diagnoses, according to NeuroOne. Thanks to NeuroOne’s partnership with Zimmer Biomet Holdings Inc. (NYSE: ZBH), the company’s technology is already being used in the marketplace. Zimmer Biomet, which is the exclusive worldwide distribution partner for the NeuroOne Evo Cortical and sEEG electrode product lines, uses it for the recording, monitoring and stimulation of electrical signals at the subsurface level of the brain. That segment of the business is growing, and the company expects its revenue to increase with the addition of new accounts by Zimmer Biomet. Making Strides With Regulators More recently, NeuroOne received U.S. Food and Drug Administration 510(k) clearance to market its OneRF™ Ablation System, a stereoelectroencephalogram (sEEG)-guided tool that surgeons can use to record electrical activity and ablate nervous tissue under temperature-controlled environments. That, along with the electrodes, has the potential to revolutionize diagnoses and treatment of brain diseases, NueroOne says. Following 510(k) clearance, NeuroOne just announced that it has initiated a limited commercial launch of its OneRF™ Ablation System, which has FDA 510(k) clearance for creation of radiofrequency (RF) lesions in nervous tissue for functional neurosurgical procedures. "The FDA clearance of NeuroOne's OneRF system will provide neurosurgeons with an important new tool in the surgical management of epilepsy, with the ability to provide ablative therapy using already implanted depth electrodes used for diagnosing the epileptic focus as part of stereoEEG,” Robert E. Gross, MD, PhD, chair of the Department of Neurosurgery at New Jersey Medical School and Robert Wood Johnson Medical School, said in a press release. “This may lead to improved outcomes for patients with potential for fewer interventions and an improved therapeutic window." In another recent press release, NeuroOne CEO Dave Rosa commented that the company expects “to start shipping systems this week to centers participating in our limited launch with cases already scheduled starting in April. We believe physicians and patients will benefit from our technology given it may reduce hospital stays, number of surgeries, and adverse events, while offering significant clinical benefits including temperature control to enhance patient safety. Looking ahead, we plan to leverage the system for other targeted ablation indications by submitting additional FDA 510(k) applications.” Pinpointing Where Seizures Occur The company’s electrodes may help pinpoint the exact location in the brain where seizures originate, which today proves difficult to do. Epileptic seizures are caused by excessive electrical discharges in a group of brain cells. Since different parts of the brain can be the site of such discharges, getting them under control is hard. After all, seizures can vary from the briefest lapses of attention or muscle jerks to severe and prolonged convulsions. They can also vary in frequency from less than one per year to several a day. Armed with more precise information from NeuroOne’s technology, medical professionals can provide patients with more accurate diagnoses and determine the best course of treatment for patients with epilepsy, according to the company. That will be welcome news to sufferers around the world. As it stands, the risk of premature death among epilepsy patients is up to three times higher than non-suffers. Currently, NeuroOne is focused on improving epilepsy diagnoses, but in the future, the focus could shift to treating seizures. For example, the company says its electrodes could be used to deliver electrical stimulation to suppress seizure activity. If they are able to achieve this, it could be game-changing for patients. It is important to note that further clinical trials are needed to determine if its electrodes can be used in the treatment of epilepsy. Epilepsy affects millions of people, costing billions of dollars annually. As it stands, more than one-third of sufferers don’t get the relief they so desperately need. NeuroOne is determined to revolutionize the landscape of neurological disorders and is making strides thanks to its unwavering dedication to developing groundbreaking products for the medical community. Featured photo by Natasha Connell on Unsplash Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

March 28, 2024 08:15 AM Eastern Daylight Time

Image
Article thumbnail News Release

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely designed to be peripherally restricted to mitigate CNS-mediated side effects associated with previous PD10 inhibitors. This design aims to ensure safety and tolerability, a primary goal in this phase of clinical research. She said the study successfully met its objectives, proving the hypothesis that peripheral restriction could eliminate adverse side effects, although it was not positioned to assess therapeutic value directly. Phelan further detailed the study's methodology, highlighting its role in estimating the pharmacologically relevant exposure and understanding the drug's exposure profile, which is critical for determining the efficacious dose for future patient trials. The interview also shed light on BenevolentAI's innovative platform that integrates diverse data types, including genomics and transcriptomics, through advanced AI and machine learning models. This platform identified PDE10 inhibition as a novel approach for treating ulcerative colitis, despite the lack of direct literature linking PDE10 to the condition, demonstrating the company's proprietary method in target discovery. Looking ahead, Phelan mentioned ongoing Biomarker Qualification studies and extended toxicology studies to pave the way for phase 1b and phase 2 studies, with an emphasis on ensuring longer dosing durations are safe for patients. This step is pivotal for moving BEN-8744 towards clinical efficacy trials, underlining BenevolentAI's commitment to advancing drug development through AI-enabled insights. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

March 28, 2024 08:12 AM Eastern Daylight Time

Video
1 23456 ... 3450